Ionis Pharmaceuticals (IONS) - Price-to-Projected Revenue Ratio

Graphic logo of Ionis (IONS)

Ionis Pharmaceuticals (IONS) focuses on developing innovative RNA-based therapies for heart and brain diseases, leveraging partners to mitigate risks. The company implements ESG principles by optimizing waste disposal and research ethics. The automation of oligonucleotide synthesis via robotics accelerates preclinical testing. The company's expected P/S ratio clearly demonstrates the link between market capitalization and revenue forecasts, while 4.70 captures the current state of the parameter.

ionispharma.com - IONS Forward P/S Multiple (period 07/04/2022 - 11/13/2026)

IONS (Isis Pharmaceuticals): analytical breakdowns and indicator data

- market price and analyst price targets:
Price Chart Ionis|IONS - Fair Value Consensus
- market capitalization indicators:
Market Value Isis Pharmaceuticals|IONS - Real Price to Acquire Entire Company
- book value of equity indicators:
Book Value per Share Ionis|IONS - Book Capitalization|Market Capitalization to Book Value Ratio ionispharma.com|IONS - Cumulative Company Assets
- debt level and financial liquidity data:
Total Debt to Capital Ionis Pharmaceuticals|IONS - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio Ionis Pharmaceuticals|IONS - Company Aggregate Debts|Debt to Book Value Isis Pharmaceuticals|IONS - Amount of Long-Term Liabilities|Company Short-Term Debts Ionis|Quick Ratio ionispharma.com
- financial results and valuation multiples details:
IONS - Net Income|Projected Future Earnings Ionis Pharmaceuticals|IONS - P/E Multiple|Future Price to Earnings Ionis Pharma|IONS - Price/Earnings to Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Isis Pharmaceuticals|IONS - Operating income before deduction of amortization|Net earnings per share (EPS TTM) Ionis|IONS - Net earnings per share for the last four quarters|Year-over-year earnings per share growth for the last twelve months ionispharma.com|IONS - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Ionis Pharmaceuticals
- total revenue and sales volume data:
IONS - Company Sales Volume|Company Projected Revenue Ionis|IONS - Price-to-Revenue Coefficient|Forward P/S Multiple Isis Pharmaceuticals
Fundamental company analysis:Ionis (IONS)
Product sample of ionispharma.com

Investors are evaluating Ionis Pharmaceuticals (IONS) through the lens of oligonucleotide synthesis robotization efficiency, which accelerates time-to-market for drugs. The forward P/S ratio compares the company's current market value with expected future sales volumes, determining the premium paid for upcoming revenue growth. Analyzing the projected P/S ratio allows for an objective assessment of the asset's fundamental attractiveness and identifies the long-term consensus point during periods of volatility.

Competing companies

Price-to-Projected Revenue Ratio Tempus AI, Inc. TEM|Forward Price to Sales QGEN|RGEN - Price-to-Projected Revenue Ratio|Avidity Corp (RNA) - Forward Price-to-Revenue Multiple|CRSP: Forward P/S Multiple|genedx.com (WGS) - Forward P/S Multiple|RARE (Ultragenyx) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Beam Therapeutics Inc (BEAM)|Forward P/S Multiple SRPT|TWST - Market Cap to Future Revenue Ratio|10x Genomics, Inc. - Forward Price-to-Revenue Multiple|Forward P/S Multiple intelliatx.com NTLA|STOK: Forward Price-to-Revenue Multiple|BioLife Solutions Inc - Price to Expected Revenue Ratio|WVE: Forward P/S Multiple|MAZE - Market Cap to Expected Sales Ratio|SION (Sionna Therapeutics Inc) - Forward P/S Multiple|Forward Price-to-Revenue Multiple primemedicine.com (PRME)|Forward P/S Multiple TSHA|Forward P/S Multiple uniQure NV (QURE)|Price-to-Projected Revenue Ratio MeiraGTx PLC MGTX|REGENXBIO Corp - Price-to-Projected Revenue Ratio|SLDB - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio ocugen.com OCGN|PACB: Forward P/S Multiple|BNTC - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Design Pharma|Market Cap to Future Revenue Ratio Rocket Corp RCKT|Price-to-Projected Revenue Ratio 4D Molecular Therapeutics (FDMT)|lexeotx.com - Market Cap to Projected Revenue|Price-to-Projected Revenue Ratio Korro Bio KRRO|Market Cap to Expected Sales Ratio Editas Medicine Inc (EDIT)|Silence Therapeutics Inc. - Forward P/S Multiple|PRQR (ProQR Therapeutics N.V.) - Market Cap to Projected Revenue|codexis.com (CDXS) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue SGMO|NAUT (Nautilus Biotechnology, Inc.) - Forward P/S Multiple|Forward P/S Multiple Metagenomi Inc.|Forward P/S Multiple DTIL|Market Cap to Expected Sales Ratio generationbio.com|Price-to-Projected Revenue Ratio Boundless Bio, Inc. BOLD|Exicure Inc. (XCUR) - Market Cap to Future Revenue Ratio|IMNN - Price-to-Projected Revenue Ratio|PHIO (Phio Pharmaceuticals) - Market Cap to Projected Revenue|MBIO: Forward P/S Multiple|RNAZ - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Bionano Genomics Inc.|adnas.com (APDN) - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple BLUE (bluebird bio)|IPA (immunoprecise.com) - Forward Price to Sales|Price-to-Projected Revenue Ratio Omega OMGA|OMIC (Singular Genomics Corp) - Future Price to Revenue|Regulus Therapeutics - Forward P/S Multiple|Forward Price to Sales SYRS (syros.com)|TBIO: Forward P/S Multiple|TRACON Pharmaceuticals Inc. (TCON) - Forward P/S Multiple|Price-to-Projected Revenue Ratio Unity Bio